Does the media favor XENE or UTHR?

In the previous week, United Therapeutics had 18 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 41 mentions for United Therapeutics and 23 mentions for Xenon Pharmaceuticals. United Therapeutics' average media sentiment score of 1.45 beat Xenon Pharmaceuticals' score of 1.39 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 32 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XENE or GMAB?

In the previous week, Xenon Pharmaceuticals had 18 more articles in the media than Genmab A/S. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 5 mentions for Genmab A/S. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Genmab A/S's score of 0.98 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XENE or BBIO?

In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 18 mentions for BridgeBio Pharma. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat BridgeBio Pharma's score of 1.17 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or XENE?

In the previous week, Xenon Pharmaceuticals had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 16 mentions for Ascendis Pharma A/S. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Ascendis Pharma A/S's score of 1.13 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EXEL or XENE?

In the previous week, Exelixis had 10 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 33 mentions for Exelixis and 23 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Exelixis' score of 1.14 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 22 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xenon Pharmaceuticals (XENE) Competitors

$59.99 -1.94 (-3.13%)

As of 08/28/2026 04:00 PM Eastern

Compare

XENE vs. UTHR, GMAB, BBIO, ASND, and EXEL

Should you buy Xenon Pharmaceuticals stock or one of its competitors? Xenon Pharmaceuticals's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xenon Pharmaceuticals compare to United Therapeutics?

Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, United Therapeutics had 18 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 41 mentions for United Therapeutics and 23 mentions for Xenon Pharmaceuticals. United Therapeutics' average media sentiment score of 1.45 beat Xenon Pharmaceuticals' score of 1.39 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	32 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Xenon Pharmaceuticals' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
United Therapeutics	41.56%	20.18%	17.98%

Xenon Pharmaceuticals presently has a consensus target price of $77.13, suggesting a potential upside of 28.58%. United Therapeutics has a consensus target price of $646.00, suggesting a potential upside of 25.32%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Xenon Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A
United Therapeutics	$3.18B	6.95	$1.33B	$27.95	18.44

Summary

United Therapeutics beats Xenon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Genmab A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals presently has a consensus target price of $77.13, indicating a potential upside of 28.58%. Genmab A/S has a consensus target price of $39.50, indicating a potential upside of 18.87%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Xenon Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Genmab A/S has a net margin of 19.08% compared to Xenon Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Genmab A/S	19.08%	14.89%	7.73%

Genmab A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A
Genmab A/S	$4.13B	5.02	$963M	$1.27	26.17

In the previous week, Xenon Pharmaceuticals had 18 more articles in the media than Genmab A/S. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 5 mentions for Genmab A/S. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Genmab A/S's score of 0.98 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals and Genmab A/S tied by winning 8 of the 16 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Xenon Pharmaceuticals (NASDAQ:XENE) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 18 mentions for BridgeBio Pharma. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat BridgeBio Pharma's score of 1.17 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A
BridgeBio Pharma	$713.07M	21.00	-$724.93M	-$3.57	N/A

Xenon Pharmaceuticals presently has a consensus price target of $77.13, suggesting a potential upside of 28.58%. BridgeBio Pharma has a consensus price target of $100.79, suggesting a potential upside of 31.58%. Given BridgeBio Pharma's higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Summary

Xenon Pharmaceuticals and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Ascendis Pharma A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.99	-$258M	$12.89	19.23
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A

Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 70.99% compared to Xenon Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

In the previous week, Xenon Pharmaceuticals had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 16 mentions for Ascendis Pharma A/S. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Ascendis Pharma A/S's score of 1.13 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S presently has a consensus target price of $302.68, suggesting a potential upside of 22.09%. Xenon Pharmaceuticals has a consensus target price of $77.13, suggesting a potential upside of 28.58%. Given Xenon Pharmaceuticals' higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Ascendis Pharma A/S beats Xenon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Exelixis has a net margin of 35.33% compared to Xenon Pharmaceuticals' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

In the previous week, Exelixis had 10 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 33 mentions for Exelixis and 23 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.39 beat Exelixis' score of 1.14 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	22 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.54	$782.57M	$3.18	17.12
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A

85.3% of Exelixis shares are held by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 8.05%. Xenon Pharmaceuticals has a consensus price target of $77.13, suggesting a potential upside of 28.58%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Exelixis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

Exelixis and Xenon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.80B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-12.66	11.62	273.16	25.45
Price / Sales	N/A	1,295.88	605.00	76.62
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	4.67	16.53	12.98	6.14
Net Income	-$345.91M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-1.28%	-0.31%	0.13%	-0.80%
1 Month Performance	-6.54%	9.80%	7.08%	4.13%
1 Year Performance	54.97%	55.66%	24.67%	15.17%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	2.5641 of 5 stars	$59.99 -3.1%	$77.13 +28.6%	+55.0%	$5.80B	N/A	N/A	210	News Coverage Positive News
UTHR United Therapeutics	4.7554 of 5 stars	$512.88 0.0%	$646.00 +26.0%	+69.1%	$22.01B	$3.18B	18.35	1,400	News Coverage Analyst Downgrade Insider Trade
GMAB Genmab A/S	3.9342 of 5 stars	$33.02 -1.3%	$39.50 +19.6%	+33.6%	$20.86B	$3.72B	26.00	3,029	Options Volume
BBIO BridgeBio Pharma	3.4598 of 5 stars	$81.07 -0.5%	$100.79 +24.3%	+48.0%	$15.93B	$502.08M	N/A	400	Positive News
ASND Ascendis Pharma A/S	4.7031 of 5 stars	$251.95 -0.5%	$300.33 +19.2%	+27.6%	$15.80B	$814.57M	19.55	1,189	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does Xenon Pharmaceuticals compare to United Therapeutics?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Xenon Pharmaceuticals compare to Exelixis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. UTHR, GMAB, BBIO, ASND, and EXEL

How does Xenon Pharmaceuticals compare to United Therapeutics?

Does the media favor XENE or UTHR?

Which has more volatility & risk, XENE or UTHR?

Is XENE or UTHR more profitable?

Do analysts recommend XENE or UTHR?

Do insiders and institutionals have more ownership in XENE or UTHR?

Which has higher earnings & valuation, XENE or UTHR?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Which has more risk and volatility, XENE or GMAB?

Do institutionals and insiders believe in XENE or GMAB?

Do analysts prefer XENE or GMAB?

Is XENE or GMAB more profitable?

Which has better valuation & earnings, XENE or GMAB?

Does the media prefer XENE or GMAB?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Does the media refer more to XENE or BBIO?

Which has higher valuation & earnings, XENE or BBIO?

Do analysts rate XENE or BBIO?

Do institutionals and insiders have more ownership in XENE or BBIO?

Is XENE or BBIO more profitable?

Which has more risk and volatility, XENE or BBIO?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Which has higher valuation and earnings, ASND or XENE?

Which has more risk & volatility, ASND or XENE?

Do institutionals and insiders have more ownership in ASND or XENE?

Is ASND or XENE more profitable?

Does the media prefer ASND or XENE?

Do analysts prefer ASND or XENE?

Summary

How does Xenon Pharmaceuticals compare to Exelixis?

Is EXEL or XENE more profitable?

Does the media favor EXEL or XENE?

Which has better valuation and earnings, EXEL or XENE?

Do insiders and institutionals have more ownership in EXEL or XENE?

Do analysts rate EXEL or XENE?

Which has more volatility and risk, EXEL or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools